Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q2 2020 Results Conference Call August 6, 2020 8:30 AM ET
Company Participants
Allen Baharaff - President and CEO
Dr. Tali Gorfine - CMO
Yohai Stenzler - CFO
Dr. Liat Hayardeny - CSO
Conference Call Participants
Steve Seedhouse - Raymond James
Ed Arce - H.C. Wainwright
Kristen Kluska - Cantor Fitzgerald
Operator
Good day, and welcome to the Galmed conference call to discuss Financial Results for the Second Quarter of 2020. Today’s conference is being recorded.
Before we begin, please note that we will be making certain forward-looking statements on today’s call, including those regarding financial results, statements and forecasts regarding anticipated time lines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events. These statements are based on beliefs and expectations of management as of today, and actual results, trends, time lines and projections relating to our financial position and projected development programs and pipeline could differ materially.
In particular, there is a significant uncertainty about the duration and severity of the COVID-19 pandemic and its impact on Galmed’s business operations. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitations, the risks under the heading, Risk Factors, described in our annual report on Form 20-F filed with the SEC and the risks and uncertainties included in the Form 6-K filed with the SEC earlier today. Galmed assumes no obligations to update any forward-looking statements or information, which speaks as of their respective dates only.
I would now like to turn the call over to Allen Baharaff, President and Chief Executive Officer. Allen, please go ahead.
Allen Baharaff
Thank you, Mary. Good morning, and thank you for joining us on today’s conference call. I’m pleased to be
- Read more current GLMD analysis and news
- View all earnings call transcripts